top
Please input keywords
포스터 다운로드
AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate
Conclusions


DM004’s parental 5T4 ADC shows excellent anti-tumor efficacy both in vitro and in vivo.


The reduced binding avidity of anti-MET monovalent antibodies suggests improved tumor selectivity for DM004 compared to anti-MET monoclonal antibody.


DM004 BsADC candidates demonstrate robust anti-tumor efficacy in CDX and PDX models with different levels of 5T4 and MET expression, indicating DM004 has a strong potential for clinical benefit.

*Name
*Email
*Telephone
*Company
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*City